Use evidence to support early coverage of gene therapy after accelerated approval; Trump surrogates hint at how he could reshape U.S. health care policy

Taking stock of the drug industry, from the lab to the medicine chest

April 23, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Opinion: Use evidence to support early coverage of gene therapy after accelerated approval With little known about the long-term risks of gene therapy, payers are reluctant to cover it. Collecting novel evidence can help. By Lee A. Fleisher and Matthew A. Fleisher STAT+ | Day One drug for common childhood brain tumor approved by FDA Researchers hope the pill, which will be marketed as Ojemda, may allow more patients to reach adulthood without highly toxic treatments such as radiation. By Jason Mast Trump surrogates hint at how he could reshape U.S. health care policy STAT spoke with people close to Trump's orbit who emphasized his interest in reshaping Medicare's drug pricing policies and taking on ACA markets. By Sarah Owermohle

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser